Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

Early sports specialization between the ages of 8 and 14 years may increase the risk for hip pain and the need for surgical ...

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and ...

Among adults with relapsing MS who received ublituximab, the annualized relapse rate continued to drop with up to 5 years of ...

With March being MS Awareness Month, we sat down with Everclear’s Art Alexakis, who was diagnosed with the chronic autoimmune disease nearly 10 years ago.

With fenebrutinib, the company aims to launch a new oral treatment for multiple sclerosis that offers both greater ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and ...

Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK inhibitor to a 12% reduction in the risk of disability progression compared to ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments. The Cambridge, Mass., biotechnology company said it expects revenue to ...